The DOI matches its Crossref record; 211 of the 211 references it cites were found in a registry or an index.
Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands
Open accessAbstract
The inflammatory chemokines CXCL9, CXCL10 and CXCL11 are predominantly induced by interferon (IFN)-γ and share an exclusive chemokine receptor named CXCR3. With a prototype function of directing temporal and spatial migration of activated T cells and natural killer (NK) cells, and inhibitory effects on angiogenesis, these CXCR3 ligands have been implicated in infection, acute inflammation, autoinflammation and autoimmunity, as well as in cancer. Intense former research efforts led to recent and ongoing clinical trials using CXCR3 and CXCR3 ligand targeting molecules. Scientific evidence has claimed mutual redundancy, ligand dominance, collaboration or even antagonism, depending on the (patho)physiological context. Most research on their in vivo activity, however, illustrates that CXCL9, CXCL10 and CXCL11 each contribute to the activation and trafficking of CXCR3 expressing cells in a non-redundant manner. When looking into detail, one can unravel a multistep machinery behind final CXCR3 ligand functions. Not only can specific cell types secrete individual CXCR3 interacting chemokines in response to certain stimuli, but also the receptor and glycosaminoglycan (GAG) interactions, major associated intracellular pathways and susceptibility to processing by particular enzymes, amongst others, seem ligand-specific. Here, we overview major aspects of the molecular properties and regulatory mechanisms of IFN-induced CXCR3 ligands, and propose that their in vivo non-redundancy is a reflection of the unprecedented degree of versatility that seems inherent to the IFN-related CXCR3 chemokine system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Chemokines — Chemotactic Cytokines That Mediate Inflammation
Luster, A. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380706 · Cited by 3,630
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Schellekens, G. A., Visser, H., De Jong, B. A. W., Van Den Hoogen, F. H. J., Hazes, J. M. W., Breedveld, F. C., & Van Venrooij, W. J. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200001)43:1<155::aid-anr20>3.0.co;2-3 · Cited by 1,450
Qin, S., Rottman, J. B., Myers, P., Kassam, N., Weinblatt, M., Loetscher, M., Koch, A. E., Moser, B., & Mackay, C. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1422 · Cited by 1,359
Burns, J. M., Summers, B. C., Wang, Y., Melikian, A., Berahovich, R., Miao, Z., Penfold, M. E. T., Sunshine, M. J., Littman, D. R., Kuo, C. J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052144 · Cited by 1,263
The Chemokine Superfamily Revisited
Zlotnik, A., & Yoshie, O. (2012) · Immunity · doi:10.1016/j.immuni.2012.05.008 · Cited by 1,235
Loetscher, M., Gerber, B., Loetscher, P., Jones, S. A., Piali, L., Clark-Lewis, I., Baggiolini, M., & Moser, B. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.963 · Cited by 1,193
Suzuki, A., Yamada, R., Chang, X., Tokuhiro, S., Sawada, T., Suzuki, M., Nagasaki, M., Nakayama-Hamada, M., Kawaida, R., Ono, M., et al. (2003) · Nature Genetics · doi:10.1038/ng1206 · Cited by 1,168
G-protein-coupled receptors and signaling networks: emerging paradigms
Marinissen, M. J., & Gutkind, J. S. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01678-3 · Cited by 1,049
CXCR3 ligands: redundant, collaborative and antagonistic functions
Groom, J. R., & Luster, A. D. (2011) · Immunology & Cell Biology · doi:10.1038/icb.2010.158 · Cited by 1,001
Groom, J. R., & Luster, A. D. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.12.017 · Cited by 988
Luster, A. D., Unkeless, J. C., & Ravetch, J. V. (1985) · Nature · doi:10.1038/315672a0 · Cited by 944
Cole, K. E., Strick, C. A., Paradis, T. J., Ogborne, K. T., Loetscher, M., Gladue, R. P., Lin, W., Boyd, J. G., Moser, B., Wood, D. E., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.2009 · Cited by 870
Bachelerie, F., Ben-Baruch, A., Burkhardt, A. M., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Sparre-Ulrich, A. H., Locati, M., Luster, A. D., et al. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.007724 · Cited by 850
Chemokine:Receptor Structure, Interactions, and Antagonism
Allen, S. J., Crown, S. E., & Handel, T. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090529 · Cited by 839
Demystifying Heparan Sulfate–Protein Interactions
Xu, D., & Esko, J. D. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035314 · Cited by 805
Proudfoot, A. E. I., Handel, T. M., Johnson, Z., Lau, E. K., LiWang, P., Clark-Lewis, I., Borlat, F., Wells, T. N. C., & Kosco-Vilbois, M. H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0334864100 · Cited by 781
Lasagni, L., Francalanci, M., Annunziato, F., Lazzeri, E., Giannini, S., Cosmi, L., Sagrinati, C., Mazzinghi, B., Orlando, C., Maggi, E., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021897 · Cited by 739
Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo.
Angiolillo, A. L., Sgadari, C., Taub, D. D., Liao, F., Farber, J. M., Maheshwari, S., Kleinman, H. K., Reaman, G. H., & Tosato, G. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.1.155 · Cited by 705
The chemokine system: redundancy for robust outputs
Mantovani, A. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01469-3 · Cited by 704
Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides
Maione, T. E., Gray, G. S., Petro, J., Hunt, A. J., Donner, A. L., Bauer, S. I., Carson, H. F., & Sharpe, R. J. (1990) · Science · doi:10.1126/science.1688470 · Cited by 697
The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases
Russo, R. C., Garcia, C. C., Teixeira, M. M., & Amaral, F. A. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.894886 · Cited by 647
The role of CXC chemokines and their receptors in cancer
Vandercappellen, J., Van Damme, J., & Struyf, S. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.050 · Cited by 643
Self-citationSierro, F., Biben, C., Martínez-Muñoz, L., Mellado, M., Ransohoff, R. M., Li, M., Woehl, B., Leung, H., Groom, J., Batten, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702229104 · Cited by 624
Dancing to the tune of chemokines
Thelen, M. (2001) · Nature Immunology · doi:10.1038/84224 · Cited by 618
Ponomaryov, T., Peled, A., Petit, I., Taichman, R. S., Habler, L., Sandbank, J., Arenzana-Seisdedos, F., Magerus, A., Caruz, A., Fujii, N., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10329 · Cited by 584
Rashighi, M., Agarwal, P., Richmond, J. M., Harris, T. H., Dresser, K., Su, M.-W., Zhou, Y., Deng, A., Hunter, C. A., Luster, A. D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007811 · Cited by 518
Fine-tuning of GPCR activity by receptor-interacting proteins
Ritter, S. L., & Hall, R. A. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2803 · Cited by 480
Classical and new roles of β-arrestins in the regulation of G-PROTEIN-COUPLED receptors
Pierce, K. L., & Lefkowitz, R. J. (2001) · Nature Reviews Neuroscience · doi:10.1038/35094577 · Cited by 476
Rules of chemokine receptor association with T cell polarization in vivo
Kim, C. H., Rott, L., Kunkel, E. J., Genovese, M. C., Andrew, D. P., Wu, L., & Butcher, E. C. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13543 · Cited by 474
Luster, A. D., Greenberg, S. M., & Leder, P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.1.219 · Cited by 446
Neuronal CXCL10 Directs CD8 + T-Cell Recruitment and Control of West Nile Virus Encephalitis
Klein, R. S., Lin, E., Zhang, B., Luster, A. D., Tollett, J., Samuel, M. A., Engle, M., & Diamond, M. S. (2005) · Journal of Virology · doi:10.1128/jvi.79.17.11457-11466.2005 · Cited by 424
Wang, L., Fuster, M., Sriramarao, P., & Esko, J. D. (2005) · Nature Immunology · doi:10.1038/ni1233 · Cited by 413
CXC chemokines: the regulatory link between inflammation and angiogenesis
Romagnani, P., Lasagni, L., Annunziato, F., Serio, M., & Romagnani, S. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.02.006 · Cited by 409
Romagnani, P., Annunziato, F., Lasagni, L., Lazzeri, E., Beltrame, C., Francalanci, M., Uguccioni, M., Galli, G., Cosmi, L., Maurenzig, L., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9775 · Cited by 379
Human Mig chemokine: biochemical and functional characterization.
Liao, F., Rabin, R. L., Yannelli, J. R., Koniaris, L. G., Vanguri, P., & Farber, J. M. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1301 · Cited by 373
Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization
Loetscher, M., Loetscher, P., Brass, N., Meese, E., & Moser, B. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199811)28:11<3696::aid-immu3696>3.0.co;2-w · Cited by 357
Chemokine/Chemokine Receptor Nomenclature
(2002) · Journal of Interferon & Cytokine Research · doi:10.1089/107999002760624305 · Cited by 353
Barreira da Silva, R., Laird, M. E., Yatim, N., Fiette, L., Ingersoll, M. A., & Albert, M. L. (2015) · Nature Immunology · doi:10.1038/ni.3201 · Cited by 337
Oravecz, T., Pall, M., Roderiquez, G., Gorrell, M. D., Ditto, M., Nguyen, N. Y., Boykins, R., Unsworth, E., & Norcross, M. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.11.1865 · Cited by 332
Mlecnik, B., Tosolini, M., Charoentong, P., Kirilovsky, A., Bindea, G., Berger, A., Camus, M., Gillard, M., Bruneval, P., Fridman, W., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.10.057 · Cited by 328
How chemokines invite leukocytes to dance
Thelen, M., & Stein, J. V. (2008) · Nature Immunology · doi:10.1038/ni.f.207 · Cited by 324
The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3
Loetscher, P., Pellegrino, A., Gong, J.-H., Mattioli, I., Loetscher, M., Bardi, G., Baggiolini, M., & Clark-Lewis, I. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005652200 · Cited by 316
Defective lymphocyte chemotaxis in β-arrestin2- and GRK6-deficient mice
Fong, A. M., Premont, R. T., Richardson, R. M., Yu, Y.-R. A., Lefkowitz, R. J., & Patel, D. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.112198299 · Cited by 311
CXCR3 ligands in disease and therapy
Van Raemdonck, K., Van den Steen, P. E., Liekens, S., Van Damme, J., & Struyf, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.11.009 · Cited by 310
Self-citationFarber, J. M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.14.5238 · Cited by 298
Hattermann, K., Held-Feindt, J., Lucius, R., Müerköster, S. S., Penfold, M. E. T., Schall, T. J., & Mentlein, R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3642 · Cited by 295
Expression and regulation of chemokine receptors in human natural killer cells
Inngjerdingen, M., Damaj, B., & Maghazachi, A. A. (2001) · Blood · doi:10.1182/blood.v97.2.367 · Cited by 290
Bracaglia, C., de Graaf, K., Pires Marafon, D., Guilhot, F., Ferlin, W., Prencipe, G., Caiello, I., Davì, S., Schulert, G., Ravelli, A., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-209020 · Cited by 290
Ichikawa, A., Kuba, K., Morita, M., Chida, S., Tezuka, H., Hara, H., Sasaki, T., Ohteki, T., Ranieri, V. M., dos Santos, C. C., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0508oc · Cited by 289
Campanella, G. S. V., Tager, A. M., El Khoury, J. K., Thomas, S. Y., Abrazinski, T. A., Manice, L. A., Colvin, R. A., & Luster, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801544105 · Cited by 288
Strieter, R. M., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., & Polverini, P. J. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1626 · Cited by 287
Chemokines and Chemokine Receptors: Biology and Clinical Relevance in Inflammation and AIDS
Locati, M., & Murphy, M. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.425 · Cited by 283
Intracellular Domains of CXCR3 That Mediate CXCL9, CXCL10, and CXCL11 Function
Colvin, R. A., Campanella, G. S. V., Sun, J., & Luster, A. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403595200 · Cited by 274
Lambeir, A.-M., Proost, P., Durinx, C., Bal, G., Senten, K., Augustyns, K., Scharpé, S., Van Damme, J., & De Meester, I. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103106200 · Cited by 271
Self-citationRabin, R. L., Park, M. K., Liao, F., Swofford, R., Stephany, D., & Farber, J. M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.7.3840 · Cited by 268
β-arrestin signaling and regulation of transcription
Ma, L., & Pei, G. (2007) · Journal of Cell Science · doi:10.1242/jcs.03338 · Cited by 268
Kaplan, G., Luster, A. D., Hancock, G., & Cohn, Z. A. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.4.1098 · Cited by 266
Vanbervliet, B., Bendriss-Vermare, N., Massacrier, C., Homey, B., de Bouteiller, O., Brière, F., Trinchieri, G., & Caux, C. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20020437 · Cited by 248
Muehlinghaus, G., Cigliano, L., Huehn, S., Peddinghaus, A., Leyendeckers, H., Hauser, A. E., Hiepe, F., Radbruch, A., Arce, S., & Manz, R. A. (2005) · Blood · doi:10.1182/blood-2004-08-2992 · Cited by 245
Ohmori, Y., & Hamilton, T. A. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53303-2 · Cited by 243
Wang, Q., Nagarkar, D. R., Bowman, E. R., Schneider, D., Gosangi, B., Lei, J., Zhao, Y., McHenry, C. L., Burgens, R. V., Miller, D. J., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901386 · Cited by 242
Proost, P., Schutyser, E., Menten, P., Struyf, S., Wuyts, A., Opdenakker, G., Detheux, M., Parmentier, M., Durinx, C., Lambeir, A.-M., et al. (2001) · Blood · doi:10.1182/blood.v98.13.3554 · Cited by 237
Self-citationHartl, D., Krauss-Etschmann, S., Koller, B., Hordijk, P. L., Kuijpers, T. W., Hoffmann, F., Hector, A., Eber, E., Marcos, V., Bittmann, I., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.8053 · Cited by 236
Chemokines: role in inflammation and immune surveillance
Moser, B., & Willimann, K. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.028316 · Cited by 220
Massena, S., Christoffersson, G., Hjertström, E., Zcharia, E., Vlodavsky, I., Ausmees, N., Rolny, C., Li, J.-P., & Phillipson, M. (2010) · Blood · doi:10.1182/blood-2010-01-266072 · Cited by 219
Hickman, H. D., Reynoso, G. V., Ngudiankama, B. F., Cush, S. S., Gibbs, J., Bennink, J. R., & Yewdell, J. W. (2015) · Immunity · doi:10.1016/j.immuni.2015.02.009 · Cited by 217
Chemokine Receptor Expression and Function in CD4+ T Lymphocytes with Regulatory Activity
Sebastiani, S., Allavena, P., Albanesi, C., Nasorri, F., Bianchi, G., Traidl, C., Sozzani, S., Girolomoni, G., & Cavani, A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.2.996 · Cited by 214
Monteclaro, F. S., & Charo, I. F. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.32.19084 · Cited by 206
Ge, L., Ly, Y., Hollenberg, M., & DeFea, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300573200 · Cited by 205
Sadir, R., Imberty, A., Baleux, F., & Lortat-Jacob, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405392200 · Cited by 205
Yamamoto, J., Adachi, Y., Onoue, Y., Adachi, Y. S., Okabe, Y., Itazawa, T., Toyoda, M., Seki, T., Morohashi, M., Matsushima, K., et al. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.68.4.568 · Cited by 195
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV
Casrouge, A., Decalf, J., Ahloulay, M., Lababidi, C., Mansour, H., Vallet-Pichard, A., Mallet, V., Mottez, E., Mapes, J., Fontanet, A., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci40594 · Cited by 189
Zohar, Y., Wildbaum, G., Novak, R., Salzman, A. L., Thelen, M., Alon, R., Barsheshet, Y., Karp, C. L., & Karin, N. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71951 · Cited by 184
Majumder, S., Zhou, L. Z.-H., Chaturvedi, P., Babcock, G., Aras, S., & Ransohoff, R. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.9.4736 · Cited by 184
Biased and G Protein-Independent Signaling of Chemokine Receptors
Steen, A., Larsen, O., Thiele, S., & Rosenkilde, M. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00277 · Cited by 181
Rani, M. R. S., Foster, G. R., Leung, S., Leaman, D., Stark, G. R., & Ransohoff, R. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.37.22878 · Cited by 180
Ge, L., Shenoy, S. K., Lefkowitz, R. J., & DeFea, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410312200 · Cited by 177
Majumder, S., Zhou, L., Chaturvedi, P., Babcock, G., Aras, S., & Ransohoff, R. M. (1998) · PubMed · Cited by 171
García-López, M. Á., Sánchez-Madrid, F., Rodríguez-Frade, J. M., Mellado, M., Acevedo, A., García, M. I., Albar, J. P., Martínez-A, C., & Marazuela, M. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780248 · Cited by 169
Jinquan, T., Jing, C., Jacobi, H. H., Reimert, C. M., Millner, A., Quan, S., Hansen, J. B., Dissing, S., Malling, H.-J., Skov, P. S., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.3.1548 · Cited by 169
Redjimi, N., Raffin, C., Raimbaud, I., Pignon, P., Matsuzaki, J., Odunsi, K. O., Valmori, D., & Ayyoub, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0579 · Cited by 168
Bao, X., Moseman, E. A., Saito, H., Petryanik, B., Thiriot, A., Hatakeyama, S., Ito, Y., Kawashima, H., Yamaguchi, Y., Lowe, J. B., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.018 · Cited by 167
CXCL9: evidence and contradictions for its role in tumor progression
Ding, Q., Lu, P., Xia, Y., Ding, S., Fan, Y., Li, X., Han, P., Liu, J., Tian, D., & Liu, M. (2016) · Cancer Medicine · doi:10.1002/cam4.934 · Cited by 164
Ectopic Lymphoid Structures: Powerhouse of Autoimmunity
Corsiero, E., Nerviani, A., Bombardieri, M., & Pitzalis, C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00430 · Cited by 164
Struyf, S., Burdick, M. D., Proost, P., Van Damme, J., & Strieter, R. M. (2004) · Circulation Research · doi:10.1161/01.res.0000146674.38319.07 · Cited by 163
Self-citationOhmori, Y., & Hamilton, T. A. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.11.5474 · Cited by 161
Hsieh, M.-F., Lai, S., Chen, J., Sung, J., Lin, Y., Wu‐Hsieh, B. A., Gerard, C. J., Luster, A. D., & Liao, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.3.1855 · Cited by 159
Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4
Jiang, D., Liang, J., Campanella, G. S., Guo, R., Yu, S., Xie, T., Liu, N., Jung, Y., Homer, R., Meltzer, E. B., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci38644 · Cited by 159
Patil, R. S., Shah, S. U., Shrikhande, S. V., Goel, M., Dikshit, R. P., & Chiplunkar, S. V. (2016) · International Journal of Cancer · doi:10.1002/ijc.30134 · Cited by 159
Tensen, C. P., Flier, J., van der Raaij-Helmer, E. M. H., Sampat-Sardjoepersad, S. C., van der Schors, R. C., Leurs, R., Scheper, R. J., Boorsma, D. M., & Willemze, R. (1999) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1999.00581.x · Cited by 154
Ehlert, J. E., Addison, C. A., Burdick, M. D., Kunkel, S. L., & Strieter, R. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.6234 · Cited by 150
Poggi, A. D., Carosio, R., Fenoglio, D., Brenci, S., Murdaca, G., Setti, M., Indiveri, F., Scabini, S., Ferrero, E., & Zocchi, M. R. (2003) · Blood · doi:10.1182/blood-2003-08-2928 · Cited by 149
Sauty, A., Colvin, R. A., Wagner, L., Rochat, S., Spertini, F., & Luster, A. D. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.7084 · Cited by 146
Sarris, M., Masson, J., Maurin, D., van der Aa, L. M., Boudinot, P., Lortat‐Jacob, H., & Herbomel, P. (2012) · Current Biology · doi:10.1016/j.cub.2012.11.018 · Cited by 145
The CXCR3 Binding Chemokine IP-10/CXCL10: Structure and Receptor Interactions
Booth, V. K., Keizer, D. W., Kamphuis, M. B., Clark‐Lewis, I., & Sykes, B. D. (2002) · Biochemistry · doi:10.1021/bi026020q · Cited by 144
Biased Agonism as a Mechanism for Differential Signaling by Chemokine Receptors
Rajagopal, S., Bassoni, D. L., Campbell, J. J., Gerard, N. P., Gerard, C. J., & Wehrman, T. S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.479113 · Cited by 144
Foxp3+IL-17+ T cells promote development of cancer-initiating cells in colorectal cancer
Yang, S., Wang, B., Chunying, G., Wu, B., Cai, C., Wang, M., Zhang, B., Liu, T., & Yang, P. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0910506 · Cited by 143
Hensbergen, P. J., Wijnands, P. G. J. T. B., Schreurs, M. W. J., Scheper, R. J., Willemze, R., & Tensen, C. P. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000165355.26795.27 · Cited by 139
Loos, T., Mortier, A., Gouwy, M., Ronsse, I., Put, W., Lenaerts, J., Damme, J. V., & Proost, P. (2008) · Blood · doi:10.1182/blood-2008-04-149039 · Cited by 138
Self-citationProost, P., Mortier, A., Loos, T., Vandercappellen, J., Gouwy, M., Ronsse, I., Schutyser, E., Put, W., Parmentier, M., Struyf, S., et al. (2007) · Blood · doi:10.1182/blood-2006-10-049072 · Cited by 138
Self-citationAddison, C. L., Arenberg, D. A., Morris, S. B., Xue, Y.-Y., Burdick, M. D., Mulligan, M. S., Iannettoni, M. D., & Strieter, R. M. (2000) · Human Gene Therapy · doi:10.1089/10430340050015996 · Cited by 136
Colvin, R. A., Campanella, G. S. V., Manice, L. A., & Luster, A. D. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00556-06 · Cited by 136
Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice
Sahin, H., Borkham‐Kamphorst, E., Kuppe, C., Zaldivar, M. M., Grouls, C., Alsamman, M., Nellen, A., Schmitz, P., Heinrichs, D., Berres, M., et al. (2012) · Hepatology · doi:10.1002/hep.25545 · Cited by 135
Blanchet, X., Langer, M., Weber, C., Koenen, R. R., & von Hundelshausen, P. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00175 · Cited by 135
Meiser, A., Müeller, A., Wise, E. L., McDonagh, E. M., Petit, S. J., Saran, N., Clark, P., Williams, T. J., & Pease, J. E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.10.6713 · Cited by 131
Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion
Wu, Q., Dhir, R., & Wells, A. H. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-3 · Cited by 129
Cox, M. A., Jenh, C., Gonsiorek, W., Fine, J. S., Narula, S. K., Zavodny, P. J., & Hipkin, R. W. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)09238-1 · Cited by 129
Loos, T., Dekeyzer, L., Struyf, S., Schutyser, E., Gijsbers, K., Gouwy, M., Fraeyman, A., Put, W., Ronsse, I., Grillet, B. A. M., et al. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700453 · Cited by 128
Self-citationProost, P., Vynckier, A., Mahieu, F., Put, W., Grillet, B. A. M., Struyf, S., Wuyts, A., Opdenakker, G., & Damme, J. V. (2003) · European Journal of Immunology · doi:10.1002/eji.200324136 · Cited by 126
Self-citationPlasmacytoid Dendritic Cell Recruitment by Immobilized CXCR3 Ligands
Kohrgruber, N., Gröger, M., Meraner, P., Kriehuber, E., Petzelbauer, P., Brandt, S., Stingl, G., Rot, A., & Maurer, D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6592 · Cited by 125
Chemokines as mediators of tumor angiogenesis and neovascularization
Keeley, E. C., Mehrad, B., & Strieter, R. M. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.10.020 · Cited by 123
Thapa, M., Welner, R. S., Pelayo, R., & Carr, D. J. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.1098 · Cited by 118
Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase
den Steen, P. E. V., Husson, S. J., Proost, P., Damme, J. V., & Opdenakker, G. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.098 · Cited by 118
Self-citationThe dependence of chemokine–glycosaminoglycan interactions on chemokine oligomerization
Dyer, D. P., Salanga, C. L., Volkman, B. F., Kawamura, T., & Handel, T. M. (2015) · Glycobiology · doi:10.1093/glycob/cwv100 · Cited by 117
The chemokine receptors CXCR4 and CXCR3 in cancer
Fulton, A. M. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0019-1 · Cited by 116
Yang, J., & Richmond, A. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.01.010 · Cited by 116
Eck, M., Schmaußer, B., Scheller, K., Brändlein, S., & Müller‐Hermelink, H. K. (2003) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2003.02305.x · Cited by 116
The human Duffy antigen binds selected inflammatory but not homeostatic chemokines
Gardner, L., Patterson, A. M., Ashton, B. A., Stone, M. A., & Middleton, J. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.06.146 · Cited by 115
Wacleche, V. S., Goulet, J.-P., Gosselin, A., Monteiro, P., Soudeyns, H., Fromentin, R., Jenabian, M.-A., Vartanian, S. M., Deeks, S. G., Chomont, N., et al. (2016) · Retrovirology · doi:10.1186/s12977-016-0293-6 · Cited by 114
Cox, J. H., Dean, R. A., Roberts, C. R., & Overall, C. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800266200 · Cited by 113
Overview of the mechanisms regulating chemokine activity and availability
Mortier, A., Damme, J. V., & Proost, P. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.04.015 · Cited by 113
Self-citationOhtani, H., Jin, Z. H., Takegawa, S., Nakayama, T., & Yoshie, O. (2008) · The Journal of Pathology · doi:10.1002/path.2448 · Cited by 111
Effect of posttranslational processing on the in vitro and in vivo activity of chemokines
Mortier, A., Gouwy, M., Damme, J. V., & Proost, P. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.11.016 · Cited by 111
Self-citationDyer, D. P., Salanga, C. L., Johns, S. C., Valdambrini, E., Fuster, M. M., Milner, C. M., Day, A. J., & Handel, T. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.720953 · Cited by 111
Berchiche, Y. A., & Sakmar, T. P. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105502 · Cited by 111
CXCL10 Can Inhibit Endothelial Cell Proliferation Independently of CXCR3
Campanella, G. S. V., Colvin, R. A., & Luster, A. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012700 · Cited by 108
Wani, N. A., Nasser, M. W., Ahirwar, D. K., Zhao, H., Miao, Z., Shilo, K., & Ganju, R. K. (2014) · Breast Cancer Research · doi:10.1186/bcr3665 · Cited by 108
Struyf, S., Salogni, L., Burdick, M. D., Vandercappellen, J., Gouwy, M., Noppen, S., Proost, P., Opdenakker, G., Parmentier, M., Gerard, C. J., et al. (2010) · Blood · doi:10.1182/blood-2009-11-253591 · Cited by 107
Self-citationChen, J., Lu, H.-L., Lai, S., Campanella, G. S. V., Sung, J., Lu, M.-Y., Wu‐Hsieh, B. A., Lin, Y., Lane, T. E., Luster, A. D., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.5.3185 · Cited by 107
Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes
Korniejewska, A., McKnight, A. J., Johnson, Z., Watson, M., & Ward, S. G. (2011) · Immunology · doi:10.1111/j.1365-2567.2010.03384.x · Cited by 102
den Steen, P. E. V., Deroost, K., Aelst, I. V., Geurts, N., Martens, E., Struyf, S., Nie, C. Q., Hansen, D. S., Matthys, P., Damme, J. V., et al. (2008) · European Journal of Immunology · doi:10.1002/eji.200737906 · Cited by 100
Self-citationThe CXC Chemokine MIG/CXCL9 Is Important in Innate Immunity againstStreptococcus pyogenes
Egesten, A., Eliasson, M., Johansson, H. M., Olin, A. I., Mörgelin, M., Müeller, A., Pease, J. E., Frick, I.-M., & Björck, L. (2007) · The Journal of Infectious Diseases · doi:10.1086/510857 · Cited by 100
Proost, P., Verpoest, S., de Borne, K. V., Schutyser, E., Struyf, S., Put, W., Ronsse, I., Grillet, B. A. M., Opdenakker, G., & Damme, J. V. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.1003524 · Cited by 99
Self-citationCrystal Structures of Oligomeric Forms of the IP-10/CXCL10 Chemokine
Swaminathan, G. J., Holloway, D. E., Colvin, R. A., Campanella, G. K., Papageorgiou, A. C., Luster, A. D., & Acharya, K. R. (2003) · Structure · doi:10.1016/s0969-2126(03)00070-4 · Cited by 98
Altara, R., Mallat, Z., Booz, G. W., & Zouein, F. A. (2016) · Journal of Immunology Research · doi:10.1155/2016/4396368 · Cited by 98
Regulation of Chemokine Activity – A Focus on the Role of Dipeptidyl Peptidase IV/CD26
Metzemaekers, M., Damme, J. V., Mortier, A., & Proost, P. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00483 · Cited by 98
Self-citationSoejima, K., & Rollins, B. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6576 · Cited by 97
Biased signaling pathways via CXCR3 control the development and function of CD4+ T cell subsets
Karin, N., Wildbaum, G., & Thelen, M. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.2mr0915-441r · Cited by 97
CXCR3 and Heparin Binding Sites of the Chemokine IP-10 (CXCL10)
Campanella, G. S. V., Lee, E. M. J., Sun, J., & Luster, A. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212077200 · Cited by 95
CXCL9, but not CXCL10, Promotes CXCR3-Dependent Immune-Mediated Kidney Disease
Weinmann‐Menke, J., Zeller, G. C., Kikawada, E., Means, T. K., Huang, X. R., Lan, H. Y., Lu, B., Farber, J. M., Luster, A. D., & Kelley, V. R. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007111179 · Cited by 95
Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker
Pandya, J. M., Lundell, A., Andersson, K. M., Nordström, I., Theander, E., & Rudin, A. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1224-1 · Cited by 92
Hasegawa, H., Inoue, A., Kohno, M., Lei, J., Miyazaki, T., Yoshie, O., Nose, M., & Yasukawa, M. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303051 · Cited by 91
Ajami, K., Pitman, M. R., Wilson, C. H., Park, J., Menz, R. I., Starr, A. E., Cox, J. H., Abbott, C. A., Overall, C. M., & Gorrell, M. D. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.02.005 · Cited by 90
Kashiwazaki, M., Tanaka, T. T., Kanda, H., Ebisuno, Y., Izawa, D., Fukuma, N., Akimitsu, N., Sekimizu, K., Monden, M., & Miyasaka, M. (2003) · International Immunology · doi:10.1093/intimm/dxg121 · Cited by 90
CXCR3 expression in human central nervous system diseases
Goldberg, S. H., van der Meer, P., Hesselgesser, J., Jaffer, S., Kolson, D. L., Albright, A. V., González‐Scarano, F., & Lavi, E. (2001) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2001.00312.x · Cited by 89
A Unique Palindromic Element Mediates Gamma Interferon Induction of mig Gene Expression
Wong, P., Severns, C. W., Guyer, N. B., & Wright, T. M. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.2.914 · Cited by 88
Xanthou, G., Williams, T. J., & Pease, J. E. (2003) · European Journal of Immunology · doi:10.1002/eji.200324235 · Cited by 88
Emerging importance of chemokine receptor CXCR3 and its ligands in cardiovascular diseases
Altara, R., Manca, M., Brandão, R. D., Zeidan, A., Booz, G. W., & Zouein, F. A. (2016) · Clinical Science · doi:10.1042/cs20150666 · Cited by 88
Ludwig, A., Schiemann, F., Mentlein, R., Lindner, B., & Brandt, E. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.1.183 · Cited by 85
Gangavarapu, P., Rajagopalan, L., Kolli, D., Guerrero-Plata, A., Garofalo, R., & Rajarathnam, K. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0511239 · Cited by 81
Rosenblum, J. M., Shimoda, N., Schenk, A. D., Zhang, H., Kish, D. D., Keslar, K., Farber, J. M., & Fairchild, R. L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903831 · Cited by 80
Eotaxin Selectively Binds Heparin
Ellyard, J. I., Simson, L., Bezos, A., Johnston, K., Freeman, C. G., & Parish, C. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608046200 · Cited by 80
Cuchacovich, M., Gatica, H., Pizzo, S. V., & Gonzalez–Gronow, M. (2001) · PubMed · Cited by 80
5' regulatory region of a novel cytokine gene mediates selective activation by interferon gamma.
Wright, T. M., & Farber, J. M. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.2.417 · Cited by 79
Chemokine isoforms and processing in inflammation and immunity
Proost, P., Struyf, S., Damme, J. V., Fiten, P., Ugarte-Berzal, E., & Opdenakker, G. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.06.009 · Cited by 78
Self-citationProost, P., Struyf, S., Loos, T., Gouwy, M., Schutyser, E., Conings, R., Ronsse, I., Parmentier, M., Grillet, B. A. M., Opdenakker, G., et al. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1997 · Cited by 77
Self-citationZoudilova, M., Min, J., Richards, H. L., Carter, D., Huang, T. Y., & DeFea, K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.055806 · Cited by 76
Saxena, A., Bujak, M., Frunza, O., Dobaczewski, M. P., González-Quesada, C. J., Lu, B., Gerard, C. J., & Frangogiannis, N. G. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu138 · Cited by 74
Pericyte Regulation of Vascular Remodeling Through the CXC Receptor 3
Bodnar, R. J., Rodgers, M. E., Chen, W. C. W., & Wells, A. H. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302012 · Cited by 73
Smith, J. S., Alagesan, P., Desai, N. K., Pack, T. F., Wu, J., Inoue, A., Freedman, N. J., & Rajagopal, S. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.108522 · Cited by 67
Severin, I. C., Gaudry, J.-P., Johnson, Z., Kungl, A. J., Jansma, A. L., Gesslbauer, B., Mulloy, B., Power, C., Proudfoot, A. E. I., & Handel, T. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.082552 · Cited by 66
Inhibition of Gαi2 Activation by Gαi3 in CXCR3-mediated Signaling
Thompson, B. D., Jin, Y., Wu, K., Colvin, R. A., Luster, A. D., Birnbaumer, L., & Wu, M. X. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610931200 · Cited by 65
Turner, J. R., Steinmetz, O. M., Stahl, R. K., & Panzer, U. (2007) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955707782331768 · Cited by 64
Vanheule, V., Janssens, R., Boff, D., Kitic, N., Berghmans, N., Ronsse, I., Kungl, A. J., Amaral, F. A., Teixeira, M. M., Damme, J. V., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.649855 · Cited by 63
Self-citationRanjbaran, H., Wang, Y., Manes, T. D., Yakimov, A. O., Akhtar, S., Kluger, M. S., Pober, J. S., & Tellides, G. (2006) · Circulation · doi:10.1161/circulationaha.106.631457 · Cited by 62
Small Molecule CXCR3 Antagonists
Andrews, S. P., & Cox, R. J. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01337 · Cited by 60
Karkada, M., Cordeiro, E., Vaci, M., McMaster, C. R., & Issekutz, T. B. (2005) · European Journal of Immunology · doi:10.1002/eji.200425885 · Cited by 59
I-TAC/CXCL11 is a natural antagonist for CCR5
Petkovic, V., Moghini, C., Paoletti, S., Uguccioni, M., & Gerber, B. O. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.1103570 · Cited by 59
Genomic organization, sequence and transcriptional regulation of the human CXCL 11 gene
Tensen, C. P., Flier, J., Rampersad, S. S., Sampat-Sardjoepersad, S. C., Scheper, R. J., Boorsma, D. M., & Willemze, R. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00084-6 · Cited by 57
Zeng, Y., Wei, L., Wu, H., Liu, L., Xu, H., Wang, J., & Chu, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.8423 · Cited by 57
Decalf, J., Tarbell, K. V., Casrouge, A., Price, J. D., Linder, G., Mottez, E., Sultanik, P., Mallet, V. O., Pol, S., Duffy, D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506145 · Cited by 56
Riva, A., Laird, M. E., Casrouge, A., Ambrozaitis, A., Williams, R. L., Naoumov, N. V., Albert, M. L., & Chokshi, S. (2014) · Hepatology · doi:10.1002/hep.27139 · Cited by 53
Microbiomic and Posttranslational Modifications as Preludes to Autoimmune Diseases
Opdenakker, G., Proost, P., & Damme, J. V. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.07.002 · Cited by 52
Self-citationDevelopment of a novel chemokine-mediated in vivo T cell recruitment assay
Campanella, G. S. V., Medoff, B. D., Manice, L. A., Colvin, R. A., & Luster, A. D. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.12.002 · Cited by 51
In vivo regulation of chemokine activity by post‐translational modification
Moelants, E. A. V., Mortier, A., Damme, J. V., & Proost, P. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.16 · Cited by 50
Self-citationEjaeidi, A. A., Craft, B. S., Puneky, L. V., Lewis, R. E., & Cruse, J. M. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.06.002 · Cited by 49
Pharmacological characterization of a small‐molecule agonist for the chemokine receptor CXCR3
Scholten, D. J., Canals, M., Wijtmans, M., de Munnik, S., Nguyen, P., Verzijl, D., de Esch, I. J. P., Vischer, H. F., Smit, M. J., & Leurs, R. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01648.x · Cited by 49
CXCL10 suppression of hem- and lymph-angiogenesis in inflamed corneas through MMP13
Gao, N., Liu, X., Wu, J., Li, J., Dong, C., Wu, X., Xiao, X., & Yu, F. X. (2017) · Angiogenesis · doi:10.1007/s10456-017-9561-x · Cited by 49
Furuya, M., Yoneyama, T., Miyagi, E., Tanaka, R., Nagahama, K., Miyagi, Y., Nagashima, Y., Hirahara, F., Inayama, Y., & Aoki, I. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.05.034 · Cited by 47
Clancy‐Thompson, E., Perekslis, T. J., Croteau, W., Alexander, M. P., Chabanet, T. B., Turk, M. J., Huang, Y. H., & Mullins, D. W. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0015 · Cited by 46
Denney, H. A., Clench, M. R., & Woodroofe, M. N. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.02.164 · Cited by 46
Pancreatic β‐Cell production of CXCR3 ligands precedes diabetes onset
Burke, S. J., Karlstad, M. D., Eder, A. E., Regal, K. M., Lu, D., Burk, D. H., & Collier, J. J. (2016) · BioFactors · doi:10.1002/biof.1304 · Cited by 46
NMR structure of CXCR3 binding chemokine CXCL11 (ITAC)
Booth, V. K., Clark‐Lewis, I., & Sykes, B. D. (2004) · Protein Science · doi:10.1110/ps.04791404 · Cited by 43
Dyer, D. P., Migliorini, E., Salanga, C. L., Thakar, D., Handel, T. M., & Richter, R. P. (2017) · Open Biology · doi:10.1098/rsob.160286 · Cited by 42
Discrimination of agonist and antagonist forms of CXCL10 in biological samples
Casrouge, A., Bisiaux, A., Stephen, L. F., Schmolz, M., Mapes, J. P., Pfister, C., Pol, S., Mallet, V. O., & Albert, M. L. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04488.x · Cited by 40
Lee, H.-H., & Farber, J. M. (2008) · Cytogenetics and Cell Genetics · doi:10.1159/000134428 · Cited by 39
Akéus, P., Langenes, V., Kristensen, J., von Mentzer, A., Sparwasser, T. D., Raghavan, S., & Quiding‐Järbrink, M. (2015) · European Journal of Immunology · doi:10.1002/eji.201445058 · Cited by 37
Furin Is a Chemokine-modifying Enzyme
Hensbergen, P. J., Verzijl, D., Balog, C. I. A., Dijkman, R., van der Schors, R. C., van der Raaij-Helmer, E. M. H., van der Plas, M. J. A., Leurs, R., Deelder, A. M., Smit, M. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312814200 · Cited by 37
Functional Toll-Like Receptor 9 Expression and CXCR3 Ligand Release in Pulmonary Sarcoidosis
Schnerch, J., Prasse, A., Vlachakis, D., Schuchardt, K. L., Pechkovsky, D. V., Goldmann, T., Gaede, K. I., Müller–Quernheim, J., & Zissel, G. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0278oc · Cited by 37
Vanheule, V., Boff, D., Mortier, A., Janssens, R., Petri, B., Kołaczkowska, E., Kubes, P., Berghmans, N., Struyf, S., Kungl, A. J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00530 · Cited by 37
Self-citationVanheule, V., Vervaeke, P., Mortier, A., Noppen, S., Gouwy, M., Snoeck, R., Andreï, G., Damme, J. V., Liekens, S., & Proost, P. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.11.001 · Cited by 34
Self-citationDifferential regulation of hyaluronan-induced IL-8 and IP-10 in airway epithelial cells
Boodoo, S., Spannhake, E. W., Powell, J. D., & Horton, M. R. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00518.2005 · Cited by 34
Fibronectin Binding Modulates CXCL11 Activity and Facilitates Wound Healing
Tortelli, F., Pisano, M., Briquez, P. S., Martino, M. M., & Hubbell, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079610 · Cited by 34
Metzemaekers, M., Mortier, A., Janssens, R., Boff, D., Vanbrabant, L., Lamoen, N., Damme, J. V., Teixeira, M. M., Meester, I. D., Amaral, F. A., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071513 · Cited by 34
Self-citationCXCR3 Deficiency Prolongs Th1-Type Contact Hypersensitivity
Suga, H., Sugaya, M., Miyagaki, T., Ohmatsu, H., Okochi, H., & Sato, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201606 · Cited by 33
Migratory Pathways of γδ T Cells and Response to CXCR3 and CXCR4 Ligands
Poggi, A. D., Zancolli, M., Catellani, S., Borsellino, G., Battistini, L., & Zocchi, M. R. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1381.008 · Cited by 31
Abboud, G., Desai, P., Dastmalchi, F., Stanfield, J., Tahiliani, V., Hutchinson, T. E., & Salek‐Ardakani, S. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20160167 · Cited by 26
Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11
Namkoong, H., Song, M.-Y., Seo, Y. B., Choi, D., Kim, S. W., Im, S. J., Sung, Y. C., & Park, Y. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.066 · Cited by 25
Cited by
Phetsouphanh, C., Darley, D. R., Wilson, D. B., Howe, A., Munier, C. M. L., Patel, S. K., Juno, J. A., Burrell, L. M., Kent, S. J., Dore, G. J., et al. (2022) · Nature Immunology · doi:10.1038/s41590-021-01113-x · Cited by 1,015
House, I. G., Savas, P., Lai, J., Chen, A. X. Y., Oliver, A. J., Teo, Z. L., Todd, K. L., Henderson, M. A., Giuffrida, L., Petley, E. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1868 · Cited by 790
“CXCL11 binds to CXCR3 with the highest affinity, followed by CXCL10 and CXCL9 (15, 16) and notably CXCL11 binds to the CXCR3 receptor at a distinct binding site of the receptor (17), potentially leading to diverse signaling outcomes (18).”
BackgroundNeutrophil chemoattractant receptors in health and disease: Double-edged swords
Metzemaekers, M., Gouwy, M., & Proost, P. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0412-0 · Cited by 570
Self-citationMouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling
Israelow, B., Song, E., Mao, T., Lu, P., Meir, A., Liu, F., Alfajaro, M. M., Wei, J., Dong, H., Homer, R. J., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201241 · Cited by 415
Commensal-driven immune zonation of the liver promotes host defence
Gola, A., Dorrington, M. G., Speranza, E., Sala, C., Shih, R. M., Radtke, A. J., Wong, H. S., Baptista, A. P., Hernandez, J. M., Castellani, G., et al. (2021) · Nature · doi:10.1038/s41586-020-2977-2 · Cited by 278
Metadata
- Authors
- Metzemaekers, M., Vanheule, V., Janssens, R., Struyf, S., & Proost, P.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-01-15
- Volume
- 8
- Pages
- 1970-1970
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2782848416
- Cited by
- 328
- References
- 211
- FWCI
- 9.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.